相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件:
Powder: -20°C, 3 years; 4°C, 2 years.In solvent: -80°C, 6 months; -20°C, 1 month.
- 库存:
货期:1-2天
- 供应商:
MedChemExpress LLC
- 规格:
10 mM * 1 mL/5 mg/10 mg/25 mg/50 mg/100 mg
| 规格: | 10 mM * 1 mL | 产品价格: | ¥385.0 |
|---|---|---|---|
| 规格: | 5 mg | 产品价格: | ¥391.0 |
| 规格: | 10 mg | 产品价格: | ¥616.0 |
| 规格: | 25 mg | 产品价格: | ¥1116.0 |
| 规格: | 50 mg | 产品价格: | ¥1788.0 |
| 规格: | 100 mg | 产品价格: | ¥2863.0 |
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
AZD2932
CAS No. : 883986-34-3
MCE 国际站:AZD2932
产品活性:AZD2932是有效的多靶点激酶抑制剂,细胞试验中的抑制VEGFR2,PDGFβ,PDGFβ 和 PDGFβ 的 IC50 值分别为8,4,7,9 nM。
研究领域:Protein Tyrosine Kinase/RTK
作用靶点:PDGFR | VEGFR | FLT3 | c-Kit
In Vitro: AZD2932 has a potent and balanced profile against PDGFβ, VEGFR-2, Flt-3 and c-Kit. It does not inhibit the various cytochrome P450 isoforms with the worst IC50 being against 2C9 (8.0 μM). AZD2932 has no activity against hERG (IC50=137 μM).
In Vivo: Twice daily oral dosing (b.i.d.) of AZD2932 10 h apart results in significant tumor growth inhibition of 64% for both 50 and 12.5 mg/kg doses on the day the control animals are terminated. Xenografts bearing non PDGFβ expressing tumor cells are also sensitive to AZD2932 treatment: growth of Calu-6 tumor is inhibited by 81% and 72% at 50 and 12.5 mg/kg b.i.d. and and LoVo tumors by 67% at 50 mg/kg b.i.d. This is due AZD2932 potent activity against VEGFR2 as well as a potential effect on pericytes and tumor-associated fibroblasts due to PDGFR a and b inhibition. AZD2932 at 3–50 mg/kg b.i.d. 10 h apart gives 60–80% inhibition of both p-VEGFR2 and p-PDGFβ in a 1:1 ratio.
相关产品:Bioactive Compound Library Plus | Kinase Inhibitor Library | Protein Tyrosine Kinase Compound Library | Anti-Cancer Compound Library | Differentiation Inducing Compound Library | Reprogramming Compound Library | Anti-Breast Cancer Compound Library | Anti-Lung Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Blood Cancer Compound Library | Angiogenesis-Related Compound Library | Anti-Liver Cancer Compound Library | Anti-Colorectal Cancer Compound Library | Anti-Pulmonary Fibrosis Compound Library | Membrane Protein-targeted Compound Library | Membrane Receptor-targeted Compound Library | Highly Selective Inhibitors Library | Cytokine Inhibitors Library | Sorafenib | Lenvatinib | Pexidartinib | Sunitinib | Regorafenib | Nintedanib | Bevacizumab | Imatinib | Semaxinib | Cabozantinib | Gilteritinib | Ponatinib | Axitinib | Midostaurin | Quizartinib | Chloramphenicol | Pazopanib | PD173074 | Pacritinib | Crenolanib | 5Z-7-Oxozeaenol | Fostamatinib | R406 | Linifanib | Tanshinone IIA | Vandetanib | Foretinib | SU 5402
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验为什么你的 qPCR 重复性差?灵敏度低?扩增易受抑制?那是你还不知道数字 PCR
for copy number analysis of the CCL4L genes." Infection, Genetics and Evolution 25 (2014): 28 - 35.4.Oxnard, Geoffrey R., et al. "Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non–small-cell lung
Characterization of the Picrotoxin Site of GABAA Receptors
. 2012. AZD‐3043: A novel, metabolically labile sedative‐hypnotic agent with rapid and predictable emergence from hypnosis. Anesthesiology 116:1267‐1277. Elliott, K.A.C
技术资料暂无技术资料 索取技术资料















